Although the immunological role of the HHLA2 signaling pathway remains unclear, a new technique that allows gastric tumor cells to express HHLA2 may enable a targeted immunotherapy that controls its signaling pathway in patients with unresectable advanced gastric cancer. Here, HHLA2 is linked to gastric neoplasm.